Skip to main content

Table 1 Maternal and Newborn characteristics according to mobile phone intervention allocation

From: Efficacy of Mobile phone use on adherence to Nevirapine prophylaxis and retention in care among the HIV-exposed infants in prevention of mother to child transmission of HIV: a randomized controlled trial

 

Intervention (n = 75)

Control (n = 75)

P value

Characteristics

n (%)

n (%)

 

Maternal characteristics

 Mean age in years (SD)*

25.9 (4.7)

26.9 (5.5)

0.2

 Married

66

(88)

65

(86.7)

0.8

Employment status

 Employed

19

(25.3)

32

(42.7)

0.02

 ANC attendance

74

(98.7)

75 (100)

0.3

 Mother has other living children

55

(73.3)

53

(70.7)

0.7

Education level

 Tertiary

6

(8)

15

(20)

0.03

 Secondary

24

(32)

21

(28)

0.6

 Primary

44

(58.7)

39

(52)

0.412

 None

1

(1.3)

 

0

NA

Socioeconomic factors

 Single roomed housing

35

(46.7)

37

(49.3)

0.7

 Electricity within house

43

(57.3)

38

(50.7)

0.4

 Cemented floor

21

(28)

21

(28)

1.0

Newborn characteristics

 Male

36

(50)

36

(50)

1.0

 Mean birth weight (SD)

3104.1 (557)

3095.8 (529.8)

0.3

Place of birth

 KEDH

50

(66.7)

54

(72.9)

0.5

 JOOTRH

15

(20)

15

(20)

1.00

 Lumumba

9 (12)

5

(6.8)

0.3

 Other

1

(1.3)

 

NA

Mode of delivery

 SVD

63

(84)

62

(82.6)

0.8

 CS

12

(16)

12

(16)

1.00

HIV-specific information

 Currently on HAART

51

(68.9)

44

(58.7)

0.2

 Currently on Option A

21

(28)

26

(34.7)

0.4

 Mean CD4 count (SD)

396.6

(254.9)

443.1

(242.1)

0.3

 HIV status disclosure to partner

61

(84.7)

60

(83.3)

0.8

 Partner tested for HIV

42

(56)

44

(58.7)

0.7

 Known HIV positive partner

31 (41.3)

31 (41.3)

1.0

  1. Option A: mother took Zidovudine during the antenatal period, starting from as early as 14 weeks of pregnancy. A single dose of NVP and Lamivudine was added during labour, and Zidovudine and Lamivudine were continued for 7 days. If the mother breastfed, the baby received NVP syrup from birth until 1 week after all exposure to breast-milk had ended. If the mother was giving the baby replacement feeding, he or she would only get either NVP or zidovudine from birth until 6 weeks of age.
  2. Option B: mother took a prophylaxis regimen consisting of 3 antiretroviral medicines during pregnancy, labour and after delivery until 1 week after all exposure to breast-milk had ended. Infants born to mothers on option B received either nevirapine or zidovudine from birth until 4–6 weeks of age, regardless of their feeding method. WHO recommended 4 possible triple antiretroviral prophylaxis regimens for option B, with the choice of regimen to be made at the country level.